FDA's consolidated campus plan
Agency has "made a lot of progress in discussions with GSA and OMB, but we haven't reached any final decisions yet" on what type of proposal the Administration will support for the overall campus project, Commissioner Kessler says following a July 13 press roundtable. Noting that the overall project could cost about $1.3 bil., Kessler suggests that determining the scope of the entire project would provide for more intelligent use of the $200 mil. appropriated for the project in FY 1993. A recent interagency report called for replacing antiquated FDA labs, but did not mention a plan for consolidation ("The Pink Sheet" June 8, In Brief). Members of Congress have called for the Administration to submit a plan for the entire project including how it will spend the $200 mil. ("The Pink Sheet" June 15, T&G-10).
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth